Adjuvant clinical trials
How each study uses Adjuvant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Adjuvant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 9
Genocea Biosciences, Inc. (3) · Ab&B Bio-tech Co., Ltd.JS (2) · BioTech Tools S.A. (2) · Serum Institute of India Pvt. Ltd. (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · MAXVAX Biotechnology Limited Liability Company (1) · PATH (1)
Often tested with
Tested in the same studies.
GEN-003 (2) · gpASIT+ (2) · Rabies Vaccines (1) · LYB005 (1) · Neoadjuvant Therapy (1) · CHO Cells (1) · AT-501 (1) · GEN-004 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Adjuvant.
- Dec 2026Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderPhase 1 · Ab&B Bio-tech Co., Ltd.JS
- Dec 2026Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderPhase 1 · Ab&B Bio-tech Co., Ltd.JS
- Jan 2027Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and OlderPhase 1 · Yikang Biotech (Suzhou) Co., Ltd.
- Nov 2027Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsPhase 2 · Serum Institute of India Pvt. Ltd.
Studies
Open first, then newest update. How each study uses Adjuvant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaNot yet recruitingPhase 2VA Office of Research and DevelopmentNCT07859592Written as LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and OlderNot yet recruitingPhase 1Yikang Biotech (Suzhou) Co., Ltd.NCT07807449Written as Adjuvant Suspension
- PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT05341193Written as Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
- Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and AboveCompletedPhase 1MAXVAX Biotechnology Limited Liability CompanyNCT05636436Written as Low dose adjuvant
- Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsActive, not recruitingPhase 2Serum Institute of India Pvt. Ltd.NCT07147400Written as MATRIX-M1 (Adjuvant) For Bedside Mixing
- Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421050Written as Subunit Influenza Vaccine (Adjuvant)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421037Written as Quadrivalent Subunit Influenza Vaccine (Adjuvant)
- A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy AdultsActive, not recruitingPhase 1Guangzhou Patronus Biotech Co., Ltd.NCT06442241Written as LYB005 low dose with adjuvant
- Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)Active, not recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05724329Written as Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy AdultsCompletedPhase 1PATHNCT04232943Written as E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)
- Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide VaccineCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03055000Written as AGS-v + adjuvant
- Dose Ranging Safety and Efficacy of Therapeutic HSV-2 VaccineCompletedPhase 2Genocea Biosciences, Inc.NCT02114060Written as Matrix-M2 Adjuvant (25μg)
- Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 StudyCompletedPhase 2Genocea Biosciences, Inc.NCT02300142Written as Matrix-M2 Adjuvant (25μg)
- A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult SubjectsCompletedPhase 1/2Medigen Vaccine Biologics Corp.NCT02436928Written as AT-501 High Dose vaccine with Adjuvant
- Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae VaccineCompletedPhase 1Genocea Biosciences, Inc.NCT01995617Written as GEN-004 Low Dose + Adjuvant
- A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)CompletedPhase 1Statens Serum InstitutNCT01049282Written as Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
- Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating AdjuvantCompletedPhase 2BioTech Tools S.A.NCT01506375Written as gpASIT+TM + adjuvant
- Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older AdultsCompletedPhase 1Immune Targeting Systems LtdNCT01701752Written as Adjuvant + TIV
- Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular CarcinomaCompletedPhase 3Yonsei UniversityNCT01088581Written as Adjuvant group
- Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen RhinoconjunctivitisCompletedPhase 1BioTech Tools S.A.NCT01111279Written as gpAST+TM/adjuvant
See all 21 studies that test Adjuvant →
Given beside what is tested · 4 — Adjuvant is usual care or a partner of the new treatment
- Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerActive, not recruitingPhase 2SOLTI Breast Cancer Research GroupNCT05296746Written as Chemotherapy (adjuvant)
- A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-driedCompletedPhase 1Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT03026972Written as Low dose adjuvant
- Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes InfectionTerminatedPhase 2Genocea Biosciences, Inc.NCT03146403Written as Matrix-M2
- Evaluating New Formulation of Therapeutic HSV-2 VaccineCompletedPhase 2Genocea Biosciences, Inc.NCT02515175Written as Matrix-M2
As the comparator · 4 — what is tested is compared with Adjuvant
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal CancerTerminatedPhase 3Ralf HofheinzNCT04495088Written as infusional 5-FU/FA "AIO" regimen (adjuvant)
- Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of AgeStatus unknownPhase 1/2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT02919293Written as Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)
- Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and OlderCompletedPhase 1SeqirusNCT00848848Written as Trivalent Influenza Vaccine + adjuvant
- Phase 1 Norwalk Vaccine StudyCompletedPhase 1LigoCyte Pharmaceuticals, Inc.NCT00806962Written as Adjuvant/Excipients